.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 091576

« Back to Dashboard
NDA 091576 describes MONTELUKAST SODIUM, which is a drug marketed by Mylan Pharms Inc, Amneal Pharms, Kremers Urban Pharms, Teva Pharms, Dr Reddys Labs Ltd, Apotex Inc, Sandoz Inc, Torrent Pharms Ltd, Accord Hlthcare, Glenmark Generics, Ajanta Pharma Ltd, Roxane, Unimark Remedies Ltd, Hetero Labs Ltd V, Cipla Ltd, Macleods Pharms Ltd, Aurobindo Pharma Ltd, Vintage Pharms Llc, Anbison Lab Co Ltd, Unichem Labs Ltd, Apotex Corp, and Jubilant Generics, and is included in forty NDAs. It is available from fifty-five suppliers. Additional details are available on the MONTELUKAST SODIUM profile page.

The generic ingredient in MONTELUKAST SODIUM is montelukast sodium. There are thirty-two drug master file entries for this compound. Sixty suppliers are listed for this compound. Additional details are available on the montelukast sodium profile page.

Summary for NDA: 091576

Tradename:
MONTELUKAST SODIUM
Applicant:
Vintage Pharms Llc
Ingredient:
montelukast sodium
Patents:0
Therapeutic Class:Respiratory Tract Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 091576

Suppliers and Packaging for NDA: 091576

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MONTELUKAST SODIUM
montelukast sodium
TABLET;ORAL 091576 ANDA Qualitest Pharmaceuticals 0603-4655 0603-4655-02 90 TABLET, FILM COATED in 1 BOTTLE (0603-4655-02)
MONTELUKAST SODIUM
montelukast sodium
TABLET;ORAL 091576 ANDA Qualitest Pharmaceuticals 0603-4655 0603-4655-16 30 TABLET, FILM COATED in 1 BOTTLE (0603-4655-16)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 10MG BASE
Approval Date:Aug 3, 2012TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc